Posts

AstraZeneca reportedly offers about $10B for Rhythm

on
Reports from Nov. 4–5 say AstraZeneca made a non-binding offer to acquire Rhythm Pharmaceuticals for about $10 billion. The Wall Street Journal reported a bid of about $124 per share; Reuters cited sources saying the proposal could reach $134 per share if milestone payments are included. Neither company had publicly confirmed a deal, and AstraZeneca declined to comment. The reported offer is not a finalized acquisition. Rhythm shares jumped after the reports, closing up 28% at $110.68 on Nov. 4, according to Reuters. Some analysts say competing bids or further negotiations are possible. They point to Rhythm’s rare-obesity treatments and potential growth opportunities, including its Prader-Willi syndrome program; other analysts suggest the reported price may not fully reflect that potential. AstraZeneca’s reported rationale is strategic: Rhythm could strengthen its rare-disease business, Alexion, and add to its presence in obesity. A bidding war is speculation, not a confirmed...

Evommune licenses Hinova’s VAV1 drug candidate in deal worth up to $1.1 billion

on

RASONQUE brings in nearly $198 million in its first five weeks

on

Minghui licenses Japan rights to TED drug for $110M upfront

on

Ultragenyx to cut about 20% of staff and discontinue Wilson disease gene therapy

on

Boehringer Ingelheim and Sino announce potential $7B-plus cancer-drug deal

on

T-Therapeutics raises $133 million to advance cancer and autoimmune therapies

on

Evident Vascular wins FDA clearance for AI-enabled IVUS platform

on

Tecvayli moves toward first-relapse use, with uptake shaped by logistics

on

Debate grows over HHS policy allowing limited compounding of six unapproved peptides

on

Cepheid wins FDA clearance for multi-virus hemorrhagic fever test

on

Sanofi ends Nurix STAT6 degrader program soon after Phase 1 launch

on

AbbVie licenses Nxera’s deprioritized IBD drug in deal worth up to $1.47 billion

on